MicroPort Scientific Corp

MicroPort Scientific has issued a voluntary announcement stating that its subsidiary, Suzhou MicroPort Orthopedics Group, signed a letter of intent on July 15, 2026, with Beijing Tinavi Medical Technologies, proposing to sell its 82.29% equity interest in Shanghai MicroPort Orthopedics Medical Technology. The transaction consideration will be paid through the issuance of new shares by Tinavi. This potential deal is still at a preliminary negotiation stage. Key terms such as the exact transfer ratio, number of shares to be issued, and issue price are subject to further commercial negotiations, and the transaction is conditional upon completion of due diligence, signing of formal agreements, and obtaining relevant regulatory approvals. Shanghai MicroPort Orthopedics serves as the core operating entity for MicroPort Scientific's international orthopedics business, focusing on the research and development of hip and knee joint prostheses and overseas sales. Its medial pivot knee prosthesis has a 17-year implant survival rate of 98.80%, covering markets including the United States, Japan, and Europe. The transaction aims to integrate high-end prosthesis products with intelligent surgical platform resources through strategic synergy with Tinavi, a leading domestic orthopedic surgical robot company, thereby enhancing long-term investment value. The announcement cautions that the potential transaction involves uncertainties and does not constitute a commitment that the deal will necessarily be implemented.